You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Tumor-toxic CD47 mAb therapy for leukemia: a proof of concept study

    SBC: VASCULOX, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): CD47 has emerged as a novel therapeutic target in hematologic cancers. Leukemias expressing the highest levels of CD47 have the worst prognosis. Increased CD47 expression is thought to protect cancer cells from phagocytic clearance by sending a don't eat me signal to macrophages via SIRPa, an inhibitory receptor that prevents phagocytosis of CD47-bearing ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  2. Monodispersed magnetic nanoparticles for improved diagnostic imaging. Phase II: S

    SBC: CONFLUENCE LIFE SCIENCES, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Pancreatic cancer (PC) is the fourth leading cause of death from cancer in the US. Treatment options for this disease are extremely limited and prognosis is poor. At present, less than 6% of PC patients are alive afterfive years with an average survival time following diagnosis of 4-6 months, which is among the lowest for all cancers. It is clear that new thera ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  3. Magnetic Flow Sorter for Pancreatic Islet Isolation

    SBC: APT THERAPEUTICS, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Bone metastasis is common in patients with advanced breast, prostate, and lung cancers as these tumors have a remarkable ability to metastasize to bone. Two-thirds of patients with metastatic bone cancer experience severe pain which is usually described as dull in character, constant in presentation, and gradually increasing in intensity with time. Bone cancer ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  4. A Novel Adherence Technology for Ophthalmic Medications

    SBC: Glycobac, LLC            Topic: NIGMS

    DESCRIPTION: Most human therapeutic glycoproteins (biologics) are manufactured using mammalian cell lines that can add the human-type glycans required for their clinical efficacy. However, mammalian cells have some serious disadvantages - it takes a longtime to establish production lines, they can contain adventitious agents, and they can produce immunogenic glycans. The baculovirus-insect cell s ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  5. Mesodissection Device Phase II

    SBC: MEDSOCKET OF MISSOURI, INC.            Topic: NLM

    DESCRIPTION (provided by applicant): Physicians, no matter how well prepared, generate an average of two clinical questions per every three patient encounters. In 2009, the 1.3 billion visits to physicians' offices, hospital outpatient departments, and hospital emergency departments produced roughly 867 million questions. Answers to such questions likely exist, typically spread among several ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  6. Anti-CD47 mAb Therapy to Improve Kidney Transplantation

    SBC: VASCULOX, INC.            Topic: NIDDK

    DESCRIPTION (provided by applicant): Organ transplantation is a lifesaving option for those with end stage renal disease. In spite of many improvements in organ procurement, transplant procedures and immune suppression, the damage done by ischemia-reperfusion injury (IRI) remains problematic, leading to primary graft nonfunctional, delayed graft function and graft failure. The critical shortage of ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  7. SBIR PHASE II TOPIC 294, DETECTION OF PROTEIN GLYCOSYLATION; HHSN261201300047C; P

    SBC: MEDIOMICS, LLC            Topic: NCI

    Not Available

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  8. Computational tools to analyze SNP data from patients with mental illness

    SBC: PARTEK, INC.            Topic: 101

    DESCRIPTION provided by applicant The broad long term objective of the proposed research is to develop and market a commercial software product that can be used to facilitate the analysis of genetic changes in order to elucidate chromosomal abnormalities that underlie diseases such as autism spectrum disorder bipolar disorder and schizophrenia Recent technological advances allow samples of ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government